Marine natural compounds as potential CBP bromodomain inhibitors for treating cancer: an in-silico approach using molecular docking, ADMET, molecular dynamics simulations and MM-PBSA binding free energy calculations.

In silico pharmacology Pub Date : 2024-09-18 eCollection Date: 2024-01-01 DOI:10.1007/s40203-024-00258-5
Md Liakot Ali, Fabiha Noushin, Eva Azme, Md Mahmudul Hasan, Neamul Hoque, Afroz Fathema Metu
{"title":"Marine natural compounds as potential CBP bromodomain inhibitors for treating cancer: an in-silico approach using molecular docking, ADMET, molecular dynamics simulations and MM-PBSA binding free energy calculations.","authors":"Md Liakot Ali, Fabiha Noushin, Eva Azme, Md Mahmudul Hasan, Neamul Hoque, Afroz Fathema Metu","doi":"10.1007/s40203-024-00258-5","DOIUrl":null,"url":null,"abstract":"<p><p>The cAMP-responsive element binding protein (CREB) binding protein (CBP), a bromodomain-containing protein, engages with multiple transcription factors and enhances the activation of many genes. CBP bromodomain acts as an epigenetic reader and plays an important role in the CBP-chromatin interaction which makes it an important drug target for treating many diseases. Though inhibiting CBP bromodomain was reported to have great potential in cancer therapeutics, approved CBP bromodomain inhibitor is yet to come. We utilized various in silico approaches like molecular docking, ADMET, molecular dynamics (MD) simulations, MM-PBSA calculations, and in silico PASS predictions to identify potential CBP bromodomain inhibitors from marine natural compounds as they have been identified as having distinctive chemical structures and greater anticancer activities. To develop a marine natural compound library for this investigation, Lipinski's rule of five was used. Sequential investigations utilizing molecular docking, ADMET studies, 100 ns MD simulations, and MM-PBSA calculations revealed that three marine compounds-ascididemin, neoamphimedine, and stelletin A-demonstrated superior binding affinity compared to the standard inhibitor, 69 A. These compounds also exhibited suitable drug-like properties, a favorable safety profile, and formed stable protein-ligand complexes. The in-silico PASS tool predicted that these compounds have significant potential for anticancer activity. Among them, ascididemin demonstrated the highest binding affinity in both molecular docking and MM-PBSA calculations, as well as a better stability profile in MD simulations. Hence, ascididemin can be a potential inhibitor of CBP bromodomain. However, in vitro and in vivo validation is required for further confirmation of these findings.</p><p><strong>Graphical abstract: </strong></p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40203-024-00258-5.</p>","PeriodicalId":94038,"journal":{"name":"In silico pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411048/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In silico pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40203-024-00258-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The cAMP-responsive element binding protein (CREB) binding protein (CBP), a bromodomain-containing protein, engages with multiple transcription factors and enhances the activation of many genes. CBP bromodomain acts as an epigenetic reader and plays an important role in the CBP-chromatin interaction which makes it an important drug target for treating many diseases. Though inhibiting CBP bromodomain was reported to have great potential in cancer therapeutics, approved CBP bromodomain inhibitor is yet to come. We utilized various in silico approaches like molecular docking, ADMET, molecular dynamics (MD) simulations, MM-PBSA calculations, and in silico PASS predictions to identify potential CBP bromodomain inhibitors from marine natural compounds as they have been identified as having distinctive chemical structures and greater anticancer activities. To develop a marine natural compound library for this investigation, Lipinski's rule of five was used. Sequential investigations utilizing molecular docking, ADMET studies, 100 ns MD simulations, and MM-PBSA calculations revealed that three marine compounds-ascididemin, neoamphimedine, and stelletin A-demonstrated superior binding affinity compared to the standard inhibitor, 69 A. These compounds also exhibited suitable drug-like properties, a favorable safety profile, and formed stable protein-ligand complexes. The in-silico PASS tool predicted that these compounds have significant potential for anticancer activity. Among them, ascididemin demonstrated the highest binding affinity in both molecular docking and MM-PBSA calculations, as well as a better stability profile in MD simulations. Hence, ascididemin can be a potential inhibitor of CBP bromodomain. However, in vitro and in vivo validation is required for further confirmation of these findings.

Graphical abstract:

Supplementary information: The online version contains supplementary material available at 10.1007/s40203-024-00258-5.

海洋天然化合物作为治疗癌症的潜在 CBP 溴链抑制剂:使用分子对接、ADMET、分子动力学模拟和 MM-PBSA 结合自由能计算的室内方法。
cAMP 反应元件结合蛋白(CREB)结合蛋白(CBP)是一种含溴结构域的蛋白,可与多种转录因子结合,增强许多基因的活化。CBP 溴化多聚体是一种表观遗传读取器,在 CBP 与染色质的相互作用中发挥着重要作用,因此成为治疗多种疾病的重要药物靶标。据报道,抑制 CBP bromodomain 在癌症治疗中具有巨大潜力,但目前还没有获得批准的 CBP bromodomain 抑制剂。我们利用分子对接、ADMET、分子动力学(MD)模拟、MM-PBSA 计算和硅学 PASS 预测等多种硅学方法,从海洋天然化合物中找出潜在的 CBP 溴链抑制剂,因为这些化合物已被确认具有独特的化学结构和更强的抗癌活性。为开发海洋天然化合物库,本研究采用了利平斯基五法则。利用分子对接、ADMET 研究、100 ns MD 模拟和 MM-PBSA 计算进行的连续研究表明,与标准抑制剂 69 A 相比,三种海洋化合物--ascididemin、neoamphimedine 和 stelletin A--表现出更强的结合亲和力。根据室内 PASS 工具的预测,这些化合物具有显著的抗癌活性潜力。其中, ascidemin 在分子对接和 MM-PBSA 计算中表现出最高的结合亲和力,在 MD 模拟中也表现出更好的稳定性。因此,升麻素可能是一种潜在的 CBP 溴链抑制剂。然而,要进一步证实这些发现,还需要体外和体内验证:在线版本包含补充材料,可查阅 10.1007/s40203-024-00258-5。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信